Accéder au contenu
Merck

Ceftriaxone-induced hemolytic anemia: case report and review of literature.

Journal of pediatric hematology/oncology (2014-06-01)
Michael S Northrop, Hemant S Agarwal
RÉSUMÉ

Ceftriaxone is a frequently used empiric antibiotic in children. Acute hemolysis is a rare side effect of ceftriaxone therapy associated with a high mortality rate. A 14-year-old boy suffering from Crohn disease developed bacterial pneumonia that was treated with ceftriaxone. We report successful management of ceftriaxone-induced hemolytic anemia (CIHA) in this patient and review the CIHA literature in pediatric patients. Early recognition of CIHA with prompt discontinuation of ceftriaxone therapy may have a beneficial role in reduction of high mortality seen in these patients.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Ceftriaxone disodium salt hemi(heptahydrate), third-generation cephalosporin antibiotic
Supelco
Ceftriaxone Sodium, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Ceftriaxone sodium, United States Pharmacopeia (USP) Reference Standard
Ceftriaxone sodium, European Pharmacopoeia (EP) Reference Standard